Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Engg, power stocks not in favour today
Thu, 20 Dec 01:30 pm

The Indian markets continued to languish in the red during the post noon trading session. Stocks from the capital goods and power spaces are amongst the top underperformers at the moment while those from the healthcare spaces managed to find some favor.

The Sensex today is trading lower by about 65 points (down 0.3%), while NSE-Nifty is trading lower by about 30 points (down 0.5%). Stocks from the midcap and small spaces are also trading lower with the BSE Mid Cap and the BSE Small Cap indices down by 0.2% and 0.4 respectively. The rupee is trading at 54.9 to the US dollar.

Stocks of pharmaceutical companies are currently trading firm led by Abbott India, Pfizer and GSK Pharma. As per reports, Lupin has received US Food and Drug Administration's (FDA) approval for Drospirenone and Ethinyl Estradiol tablets - an oral contraceptive drug - for the American market. This is the generic version of Bayer's Yasmin tablets used for prevention of pregnancy in women. It is believed that Yasmin tablets have a sale of about US$ 275 m about (Rs 15 bn) annually. It is further reported that this is Lupin's seventh approval in the oral contraceptive space. The American oral contraceptive market is believed to have a size of about US$ 5 bn, having a growth rate of about 8 to 10%.

Stocks from the capital goods space are trading weak with Crompton Greaves and Bharat Heavy Electricals Ltd leading the pack of losers. As per reports Larsen & Toubro has bagged orders worth about Rs 11 bn in its construction division over the past month and a half. A key order was of the company's building and factories business which won an order worth Rs 8.5 bn to design and construct a major information technology campus in the National Capital Region, New Delhi. In addition, the business segment also won orders to construction multi story residential towers in Bengaluru from major clients. Further, L&T construction's metallurgical and minerals handling business - as part of a consortium with LUET China - secured orders worth of over Rs 2 bn Steel Authority of India Limited for rebuilding and construction of a coke oven battery at Durgapur Steel Plant. It may be noted that during the quarter ended September 2012, the company won order worth Rs 209.6 bn, a growth of 30% YoY. The total order book at the end of the quarter stood at Rs 1,585.2 bn.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Engg, power stocks not in favour today". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.